Medicine
Tumor Lysis Syndrome Prophylaxis and Treatment in Hematologic Malignancies
Quick fact
In high-risk hematologic malignancies like Burkitt lymphoma or acute lymphoblastic leukemia, up to 20% of patients develop tumor lysis syndrome, and without prophylaxis, it can be fatal within hours of starting chemotherapy.
Why this is interesting
Chemotherapy is meant to kill cancer cells, but when it works too quickly, it can flood the body with toxic debris. Why would a life-saving treatment suddenly cause kidney failure and cardiac arrest?
Read the full explanation
Understanding Tumor Lysis Syndrome Prophylaxis and Treatment in Hematologic Malignancies
Imagine cancer cells as tiny balloons filled with salty water, minerals, and genetic material. When chemotherapy ruptures them, all that content spills into the bloodstream at once. In hematologic cancers like leukemias and lymphomas, there can be trillions of cells, so the spill is massive. The body suddenly faces high levels of potassium (which can stop the heart), phosphate (which combines with calcium and forms crystals), and uric acid (a breakdown product of DNA that also crystalizes). These crystals clog the kidney's filtering tubes, leading to acute kidney injury. Other metabolic imbalances like hypocalcemia and hyperkalemia can then cause life-threatening arrhythmias. To prevent this, doctors assess risk before giving chemotherapy and start hydration, electrolyte monitoring, and medications that reduce uric acid production or break it down.
A deeper explanation
The core mechanism of tumor lysis syndrome is the rapid lysis of malignant cells, releasing intracellular contents. Hematologic malignancies often have high cell turnover and large tumor burden, so they are especially prone. The cascade begins with nucleic acid degradation: purines (adenine and guanine) from lysed cells are metabolized to hypoxanthine, then to xanthine, and finally to uric acid by xanthine oxidase. The resulting hyperuricemia can precipitate in the acidic renal tubules, causing obstruction. Meanwhile, phosphate released from cells binds with calcium, forming calcium phosphate deposits in kidneys and causing hypocalcemia, which can lead to tetany and arrhythmias. The high potassium load from lysed cells can cause hyperkalemia, a medical emergency that can trigger cardiac arrest. Prophylaxis therefore focuses on reducing uric acid production (allopurinol inhibits xanthine oxidase) or converting uric acid to a soluble form (rasburicase provides urate oxidase), along with aggressive hydration to dilute the urine and increase flow, and careful monitoring. Treatment of established TLS intensifies these measures and adds dialysis when conservative management fails. Understanding this mechanism highlights why prevention and early recognition are critical, as the syndrome can progress rapidly and is largely preventable with appropriate pre-chemotherapy management.